Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors

See allHide authors and affiliations

Science  05 Jan 2001:
Vol. 291, Issue 5501, pp. 134-137
DOI: 10.1126/science.291.5501.134

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Most traditional cytotoxic anticancer agents ablate the rapidly dividing epithelium of the hair follicle and induce alopecia (hair loss). Inhibition of cyclin-dependent kinase 2 (CDK2), a positive regulator of eukaryotic cell cycle progression, may represent a therapeutic strategy for prevention of chemotherapy-induced alopecia (CIA) by arresting the cell cycle and reducing the sensitivity of the epithelium to many cell cycle–active antitumor agents. Potent small-molecule inhibitors of CDK2 were developed using structure-based methods. Topical application of these compounds in a neonatal rat model of CIA reduced hair loss at the site of application in 33 to 50% of the animals. Thus, inhibition of CDK2 represents a potentially useful approach for the prevention of CIA in cancer patients.

  • * To whom correspondence should be addressed. E-mail: std41085{at}

  • Present address: Neurocrine Biosciences, 10555 Science Center Drive, San Diego, CA 92121, USA.

  • Present address: Pennie & Edmonds LLP, 3300 Hillview Avenue, Palo Alto, CA 94304, USA.

  • § Present address: Pfizer Inc., Pfizer Central Research, Eastern Point Road, Groton, CT 06340, USA.

  • || Present address: Hoffman–La Roche Inc., 340 Kingsland Street, Nutley, NJ 07110, USA.

View Full Text